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Within minutes following a myocardial infarction (MI),
neutrophils, monocytes, and macrophages are recruited to the
damaged heart. The speciﬁc role of the different macrophage
subsets in myocardial recovery and remodeling is not well
understood. In this issue of the Journal, Courties et al. (1)
used a transient gene delivery system to knock down inter-
feron regulatory factor 5 (IRF5), which decreased a subset of
classic inﬂammatory macrophage cells (M1) and decreased
inﬂammation in the mouse heart following an MI.
See page 1556
The authors used the well-characterized apolipoprotein
E/ mouse fed a high cholesterol diet for 6 months. The
mice underwent a permanent coronary artery ligation to
induce an MI (1). IRF5 was down-regulated using a small
interfering ribonucleic acid (siRNA) approach. The authors
tested multiple siRNA sequences in vitro to determine the
best candidate for IRF5 knockdown (1). The siRNA IRF5
(siIRF5) and control sequences were encapsulated in nano-
delivery capsules and injected into the tail vein 4 days post–
coronary ligation (1). Mice receiving the siIRF5 exhibited a
decrease in macrophage and monocyte IRF5 staining in-
tensity, macrophage and monocyte (Ly-6Chigh) number,
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IL-6 matrix metalloproteinase [MMP]-9 IL-10, and
transforming growth factor beta [TGF-beta]); all at day 4,
the same day as the injection (1). These mice also exhibited
decreased staining in the infarct for myeloid cells and
macrophages at day 7. Computed tomography imaging
showed decreased end-systolic and -diastolic volumes in
mice receiving siIRF5.
Because monocytes are activated and mature into macro-
phages, they can adopt a wide spectrum of functional phe-
notypes, depending upon stimuli and genetic programs. The
2 well-established polarization phenotypes are classically
activated (M1) and alternatively activated (M2) macrophages
that are responsible for inﬂammatory and anti-inﬂammatory
processes, respectively. The processes are regulated by a
complex network of factors, including transcription factors/
cofactors and extracellular signals (2). Whether macrophages
can switch back and forth between M1 and M2 remains a
widely debated topic, but major transcription factors/
cofactors and extracellular stimuli for M1 versus M2 polar-
ization have been identiﬁed. Coercing macrophage polari-
zation seems to be an attractive and feasible strategy for
decreasing inﬂammation. Previous studies have tested this
primarily by targeting transcription factor regulators
(reviewed elegantly in Tugal et al. [3]). Of particular interest
is to suppress M1 inﬂammatory responses to combat various
disease conditions as was performed by Courties et al. (1).
The majority of studies have targeted interferons or signal
transducer and activator of transcription to modulate the M1
cell population (3). However, nuclear factor kappaB and
related molecules, as well as activator protein-1, peroxisome
proliferator-activated receptors, and hypoxia-inducible
factor-1, have also been targeted (3). One successful strat-
egy used to suppress M1 inﬂammatory responses has been to
dampen a key cofactor of the nuclear factor kappaB pathway,
receptor interacting protein 140 (4). Receptor interacting
protein 140 degradation resolved inﬂammation and suc-
cessfully protected mice from septic shock (4). Courties et al.
(1) used siRNA in vivo to transiently suppress IRF5, one of
the major transcription factors for M1 macrophages (5,6),
and validated successful suppression of M1 polarization
following MI and skin wounds by measuring the expression
of a panel of marker genes. As expected, they detected a
transient reduction in levels of inﬂammatory cytokines tumor
necrosis factor alpha, IL-1beta, and IL-6 (1). Phenotypic
outcome indeed supported that reducing the number of in-
ﬂammatory macrophages, even transiently, can be beneﬁcial
and justiﬁes future exploration into this attractive strategy. In
particular, the transient nature of the manipulation strategy
adopted by Courties et al. (1) is appealing from the stand-
point of transient inﬂammation and might prove more
feasible in future clinical applications. However, the kinetics
of macrophage turnover are not discussed in this study, and it
is not clear how effective this strategy is in impacting a sec-
ondary downstream phenotype like remodeling following an
MI (even if the remodeling is dependent in part upon
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1568inﬂammation). Macrophage turnover kinetics are known to
be fast in the infarcted myocardium (7). Newly recruited
macrophages may quickly replace the previous siRNA-
targeted macrophages before any functional improvements
can be detected. Whether a single injection of siRNA against
IRF5 is able to impact the macrophage population for a long
enough time to signiﬁcantly improve the course of healing or
function remains to be determined in the mouse model. The
authors did not report ejection fraction nor did they report
starting and end values for wall thickness.
An interesting ﬁnding of this study is the lack of apparent
M2 polarization following M1 suppression for the time
points collected. Although this study conﬁrmed that
manipulating IRF5 could reduce M1 polarization, the notion
that silencing IRF5 “reprograms macrophage polarization
toward M2” was not validated because the expression of
IL-10 and TGF-beta remained unchanged. However,
because the silencing reagent was provided transiently and
ﬂuorescence-activated cell sorting analyses were not extended
to a later time, it is still possible that the M2 population
might have been altered later as a result of a reduced M1
population. This would be interesting to evaluate in the
future. Finally, questions that arise with the injection of
siRNA into the tail vein of the mice are “Where does the
greatest percentage of the injected siRNA reside?” and
“What percentage of the injected siRNA actually reached the
target of interest?” A whole-body analysis including the
circulation to assess where the injected siRNA was located
would have been helpful. However, these initial studies look
quite promising.
Nahrendorf and Swirski are establishing themselves as
new leaders in the complex ﬁeld of monocyte and macro-
phage biology in the realm of cardiovascular health and
disease. The major strength of the study is the new pre-
clinical therapeutic testing of macrophage polarization to
cardiovascular disease. We encourage all readers to follow
the paper by Courties et al. (1) to extract a current and
impressive overview provided on macrophage polarity and an
original set of exciting pre-clinical experiments to test howmanipulating macrophage polarity can alter the course of an
MI. Recent human data showing an association between
high M1 levels and atherosclerosis supports this ﬁnding (8).
Secondly, data showing that mesenchymal stem cell therapy
in the infarcted mouse heart recruits additional M2 or anti-
inﬂammatory macrophages also supports a role for macro-
phage subpopulation repair (9).
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